# Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Canonical URL: https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs
Ticker: NERV
Company: Minerva Neuroscience
Source: Minerva Neuroscience
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.minervaneurosciences.com
## Summary

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on

## Article Body
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on
## Recent Company News
- 2026-06-25 13:46 EST — [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs) — Source: Minerva Neuroscience
- 2026-06-25 13:46 EST — [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Minerva Neuroscience
- 2026-06-25 13:46 EST — [Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-reports-third-quarter-2025-financial-results-and-business-updates) — Source: Minerva Neuroscience
- 2026-06-25 13:46 EST — [Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors](https://biopharmsignal.com/news/NERV/minerva-neurosciences-appoints-dr-inderjit-kaul-to-the-company-s-board-of-directors) — Source: Minerva Neuroscience
- 2026-06-25 13:46 EST — [Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-host-virtual-kol-event-to-discuss-roluperidone-from-unmet-need-to-reality-potentially-the-first-treatment-for-patients-with-negative-symptoms-of-schizophrenia-on-february-3-2026) — Source: Minerva Neuroscience
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)